NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
Portfolio Pulse from Benzinga Newsdesk
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced promising results from its preclinical study KO-874 on mazindol's neuroprotective effects in a narcoleptic-like rat model. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) in Miami.
May 28, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NLS Pharmaceutics Ltd. reported promising preclinical results for mazindol, which could positively impact its stock price in the short term.
Positive preclinical results often lead to increased investor confidence and potential stock price appreciation, especially for clinical-stage biopharmaceutical companies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
NLS Pharmaceutics Ltd. reported promising preclinical results for mazindol, which could positively impact its stock price in the short term.
Positive preclinical results often lead to increased investor confidence and potential stock price appreciation, especially for clinical-stage biopharmaceutical companies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100